Equities

Tissue Regenix Group PLC

TRX:LSE

Tissue Regenix Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)61.50
  • Today's Change0.00 / 0.00%
  • Shares traded1.59k
  • 1 Year change7.89%
  • Beta2.0015
Data delayed at least 20 minutes, as of May 03 2024 13:26 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Tissue Regenix Group PLC grew revenues 20.50% from 24.48m to 29.49m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -2.70m to -1.71m.
Gross margin47.60%
Net profit margin-5.62%
Operating margin-1.34%
Return on assets-3.71%
Return on equity-5.58%
Return on investment-4.17%
More ▼

Cash flow in USDView more

In 2022, cash reserves at Tissue Regenix Group PLC fell by 1.76m. Cash Flow from Financing totalled 910.00k or 3.72% of revenues. In addition the company used 1.29m for operations while cash used for investing totalled 1.08m.
Cash flow per share-0.0077
Price/Cash flow per share--
Book value per share0.3406
Tangible book value per share0.1696
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.